Viral Conjunctivitis Drugs Market
Description
Viral Conjunctivitis Drugs Market, By Drug Class (Antibiotics, Artificial tears, Decongestants, Anti-histamines, NSAIDS, Anti-Viral drugs, Others (Steroids, etc.)), By Virus Type (Adenovirus, Enterovirus, Others (Herpes Simplex Virus (HSV), etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Viral conjunctivitis is an acute conjunctival infection that is caused by various viruses, such adenovirus, herpes simplex virus, etc. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases. Characteristics of ocular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia, etc. Viral conjunctivitis that is caused by a group of adenoviruses is called epidemic keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2021, adenoviral conjunctivitis is the most common type of eye infection in the adult population. Adenoviral conjunctivitis is highly contagious, as the virus causing the infection can survive on a countertop or a similar surface for several weeks.Market Dynamics
Market players are engaged in various inorganic activities such as acquisitions of companies, product approval, and others, which in turn is expected to drive growth of the global viral conjunctivitis drugs market over the forecast period. For instance, on February 2020, Bausch Health Companies Inc.’s wholly owned subsidiary, Eton Pharmaceuticals, Inc., a pharmaceutical company, announced that they had acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, would be the first over-the-counter (OTC) preservative-free formulation eye drop to be used for the treatment of ocular itching associated with conjunctivitis.
Furthermore, in July 2020, Alcon, the global leader in eye care, announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, had been approved by the U.S. Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the U.S. Pataday Once Daily Relief Extra Strength is the first and only once-daily eye allergy itch drop offering a full 24 hours of relief without a prescription. Allergies are the sixth-leading cause of chronic illness in the U.S., generating approximately US$ 2.7 billion in OTC retail sales.
Key features of the study:
- This report provides an in-depth analysis of the global viral conjunctivitis drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global viral conjunctivitis drugs market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., Santen Pharmaceutical Co.Ltd., Alcon and Okogen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral conjunctivitis drugs market.
- By Drug Class:
- Antibiotics
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Others (Steroids, etc.)
- By Viral Type:
- Adenovirus
- Enterovirus
- Others (Herpes Simplex Virus (HSV), etc.)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.m.b.H
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.
Table of Contents
214 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
